For the quarter ended February 2025, Neogen (NEOG) reported revenue of $220.98 million, down 3.4% over the same period last year. EPS came in at $0.10, compared to $0.12 in the year-ago quarter.
The reported revenue represents a surprise of -0.92% over the Zacks Consensus Estimate of $223.03 million. With the consensus EPS estimate being $0.13, the EPS surprise was -23.08%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Animal Safety: $68.25 million compared to the $68.77 million average estimate based on three analysts. The reported number represents a change of -4% year over year.
- Revenues- Food Safety: $152.73 million compared to the $154.26 million average estimate based on three analysts. The reported number represents a change of -3.2% year over year.
- Revenues- Food Safety- Indicator Testing, Culture Media & Other: $77.74 million compared to the $78.53 million average estimate based on two analysts. The reported number represents a change of -4.2% year over year.
- Revenues- Animal Safety- Life Sciences: $1.50 million versus $1.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.
- Revenues- Animal Safety- Veterinary Instruments & Disposables: $15.41 million compared to the $17.93 million average estimate based on two analysts. The reported number represents a change of -14.3% year over year.
- Revenues- Animal Safety- Animal Care & Other: $10.50 million compared to the $10.15 million average estimate based on two analysts. The reported number represents a change of +4.3% year over year.
- Revenues- Food Safety- Natural Toxins & Allergens: $17.60 million compared to the $19.62 million average estimate based on two analysts. The reported number represents a change of -10.9% year over year.
- Revenues- Animal Safety- Genomics Services: $17.01 million versus $6.43 million estimated by two analysts on average.
- Revenues- Food Safety- Genomics Services: $5.70 million versus the two-analyst average estimate of $18.46 million.
- Revenues- Food Safety- Rodent Control, Insect Control & Disinfectants: $11.82 million compared to the $10.72 million average estimate based on two analysts. The reported number represents a change of +16.6% year over year.
- Revenues- Food Safety- Bacterial & General Sanitation: $39.88 million versus $39.60 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.3% change.
- Revenues- Animal Safety- Rodent Control, Insect Control & Disinfectants: $23.83 million compared to the $21.16 million average estimate based on two analysts. The reported number represents a change of +3.4% year over year.
View all Key Company Metrics for Neogen here>>>
Shares of Neogen have returned -28.8% over the past month versus the Zacks S&P 500 composite's -13.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neogen Corporation (NEOG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.